Novartis has entered a global license and collaboration agreement with Arrowhead Pharmaceuticals, investing $200 million upfront to develop Arrowhead's preclinical siRNA therapy ARO-SNCA targeting alpha-synuclein in synucleinopathies, including Parkinson’s disease. Arrowhead’s Targeted RNAi Molecule (TRiM) platform allows simplified subcutaneous CNS drug delivery. The deal includes potential milestone payments totaling over $2 billion and enables Novartis exclusive rights to develop and commercialize this and other targets outside China. This partnership aligns with Novartis’ focus on novel RNA medicines for neurodegenerative diseases, with Arrowhead handling preclinical research and Novartis managing clinical development and commercialization.